LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Endobronchial Tuberculosis in an HIV-positive Case.

    Gegin, Savaş / Özdemir, Burcu / Günal, Özgür / Topal, Şeyma / Uzun, Çiğdem / Özdemir, Levent

    Current HIV research

    2024  

    Abstract: Introduction: Tuberculosis is an opportunist infection that is fatal and most frequently seen in HIV-positive patients due to immunosuppression. Endobronchial lesions can portray symptoms in different ways. Endobronchial Tuberculosis is one of these ... ...

    Abstract Introduction: Tuberculosis is an opportunist infection that is fatal and most frequently seen in HIV-positive patients due to immunosuppression. Endobronchial lesions can portray symptoms in different ways. Endobronchial Tuberculosis is one of these lesions.
    Case report: An HIV-positive, untreated 26-year-old patient with fever, cough, and dyspnea consulted our clinic. In the chest X-ray taken, effusion on the right side and non-homogeneous density increase in the middle and upper lobes, bilaterally more prominent on the right side, were observed. Therefore, the patient underwent bronchoscopy because the CT (computerized tomography) showed mediastinal lymphadenopathy (LAP) and an endobronchial lesion in the left main bronchus. During bronchoscopy, a vegetative endobronchial lesion that causes obstruction in the left main bronchus was monitored. With the help of Pathology and PCR results, endobronchial tuberculosis was diagnosed.
    Conclusion: Even if Acid-alcohol-resistant Bacillus (ARB) is detected negative in patients who stop responding to antimicrobial treatment and are being monitored under radiological scanning, a distinctive diagnosis of endobronchial tuberculosis should be kept in mind while performing bronchoscopy.
    Language English
    Publishing date 2024-01-24
    Publishing country Netherlands
    Document type Case Reports
    ZDB-ID 2192348-6
    ISSN 1873-4251 ; 1570-162X
    ISSN (online) 1873-4251
    ISSN 1570-162X
    DOI 10.2174/011570162X262663231214053029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: HIV-1 Enfekte Bireylerde İnsan Lökosit Antijeni (HLA)-B*57:01 Pozitifliği Prevalansının Dağılımı ve Tedavi Üzerine Etkileri: Türkiye Haritası-BUHASDER Çalışma Grubu.

    Büyüktuna, Seyit Ali / Öksüz, Caner / Tahmaz, Alper / Sarıgül Yıldırım, Figen / Türken, Melda / Günal, Özgür / Topal, Şeyma / Baran, Ali İrfan / Sarıkaya, Burak / Çelik Ekinci, Semiha / Kaya, Selçuk / Alkan Çeviker, Sevil / Aypak, Adalet / Yürük Atasoy, Pınar / İnan, Dilara / Köse, Adem / Koç İnce, Nevind / Şenbayrak, Seniha / Kaya, Şafak /
    Özgüler, Müge / Dindar Demiray, Emine Kübra / Köse, Şükran

    Mikrobiyoloji bulteni

    2023  Volume 58, Issue 1, Page(s) 29–38

    Abstract: Human immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of individuals in all age groups. The landscape of HIV ... ...

    Title translation Distribution of the Prevalence of Human Leukocyte Antigen (HLA)-B*57:01 Positivity in HIV-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Group.
    Abstract Human immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of individuals in all age groups. The landscape of HIV infection has changed significantly in recent years due to the introduction of effective combination antiretroviral therapies (ART). A key component of first-line ART regimens for HIV treatment is abacavir, a nucleoside HIV reverse transcriptase inhibitor. Although abacavir is effective in suppressing viral replication and managing disease, its clinical utility is overshadowed by the potential for life-threatening hypersensitivity reactions in HLA-B*57:01-positive patients. In our country, local data obtained from various centers regarding the prevalence of HLA-B*57:01 in HIV-1-infected patients are available. In this study, it was aimed to determine the prevalence of the HLA-B*57:01 genotype in HIV-infected patients who were followed up and treated in many regions of our country. This retrospective study consists of the data of the patients aged 18 years and over diagnosed with HIV-1 infection between 01.01.2019 and 31.07.2022. Age, gender, place of birth, mode of transmission of the disease, death status, CD4+ T cell count and HIV RNA levels at the first clinical presentation, HLA-B*57:01 positivity, and the method used, clinical stage of the disease, virological response time with the treatment they received were recorded from the patient files. Data were collected from 16 centers and each center used different methods to detect HLA-B*57:01. These methods were sequence-specific oligonucleotide probe hybridization (SSOP), DNA sequence-based typing (SBT), single-specific primer-polymerase chain reaction (SSP-PCR), allele-specific PCR (AS-PCR) and quantitative PCR (Q-PCR). A total of 608 HIV-infected individuals, 523 males (86%) and 85 females (14%), were included in the study. The mean age of the patients was 36.9 ± 11.9 (18-73) years. The prevalence of HLA-B*57:01 allele was found to be 3.6% (22 patients). The number of CD4+ T lymphocytes in HLA-B*57:01 allele-positive patients was > 500/ mm3 in 10 patients (45.5%), while the number of CD4+ T lymphocytes in HLA-B*57:01 negative patients was > 500/mm3 in 216 patients (36.9%) (p> 0.05). Viral load at the time of diagnosis was found to be lower in patients with positive HLA-B*57:01 allele but it was not statistically significant (p> 0.05). Although different treatment algorithms were used in the centers following the patients, it was observed that the duration of virological response was shorter in HLA-B*57:01 positive patients (p= 0.006). Although the presence of the HLA-B*57:01 allele has a negative impact due to its association with hypersensitivity, it is likely to continue to attract interest due to its association with slower progression of HIV infection and reduced risk of developing AIDS. In addition, although the answer to the question of whether it is cost-effective to screen patients for HLA-B*57:01 before starting an abacavir-containing ART regimen for the treatment of HIV infection is being sought, it seems that HIV treatment guidelines will continue to recommend screening to identify patients at risk in this regard.
    MeSH term(s) Female ; Male ; Humans ; Adolescent ; Adult ; Middle Aged ; HIV-1 ; Prevalence ; HIV Infections ; Acquired Immunodeficiency Syndrome ; Quality of Life ; Retrospective Studies ; Turkey ; HLA Antigens ; Cyclopropanes ; Dideoxyadenosine/analogs & derivatives
    Chemical Substances abacavir (WR2TIP26VS) ; HLA Antigens ; Cyclopropanes ; Dideoxyadenosine (4Q86AH641A)
    Language Turkish
    Publishing date 2023-03-05
    Publishing country Turkey
    Document type English Abstract ; Journal Article
    ZDB-ID 985146-x
    ISSN 0374-9096
    ISSN 0374-9096
    DOI 10.5578/mb.20249903
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top